Monoclonall antibody capable of recognizing high-risk HPV E7 protein, and applications thereof

An antibody and recombinant protein technology, applied in applications, antibodies, antiviral immunoglobulins, etc., can solve the problems of heavy workload of pathologists, restricting the efficiency and coverage of early diagnosis of cervical cancer, etc.

Active Publication Date: 2018-01-09
ATTOGEN BIOMEDICAL SUZHOU INC
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cytological interpretation requires morphological evidence, which is unavoidable subjectivity and causes extremely heavy workload for pathologists
These factors have greatly restricted the efficiency and coverage of early diagnosis and individualized treatment of cervical cancer in my country.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonall antibody capable of recognizing high-risk HPV E7 protein, and applications thereof
  • Monoclonall antibody capable of recognizing high-risk HPV E7 protein, and applications thereof
  • Monoclonall antibody capable of recognizing high-risk HPV E7 protein, and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0171] Preparation of monoclonal antibodies

[0172] Antibodies of the present invention can be prepared by various techniques known to those skilled in the art. For example, an antigen of the invention may be administered to an animal to induce the production of monoclonal antibodies. For monoclonal antibodies, hybridoma technology can be used to prepare (see Kohler et al., Nature 256; 495, 1975; Kohler et al., Eur.J.Immunol.6:511, 1976; Kohler et al., Eur.J.Immunol. 6:292,1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981), phage display technology or available recombinant DNA method (US Patent No. 4,816,567).

[0173]Representative myeloma cells are those that fuse efficiently, support stable high-level production of antibody by selected antibody-producing cells, and are sensitive to culture medium (HAT medium matrix), including myeloma cell lines, such as murine Myeloma cell lines, including those derived from MOPC-21 and MPC-11...

Embodiment 1

[0208] 1. Preparation of rabbit monoclonal antibody against human papillomavirus HPV16E7

[0209] 1.1 Screening of single-chain antibody (scFv)

[0210] Rabbits were immunized with His-HPV16E7 recombinant protein, and the titer was detected with His-HPV16E7 recombinant protein and His irrelevant protein. Isolation of rabbit B lymphocytes to obtain immunoglobulin genes. The complete set of variable region genes of B cells is cloned and assembled into a phage antibody library. The constructed phage antibody library was panned with the recombinant protein His-HPV16E7. Enrichment after three rounds of panning; determination of phage titer; amplification of phage plaques; DNA sequencing; Among them, the recombinant protein His-HPV16E7 was selected for ELISA detection and screening, and the negative control (N) was set with His irrelevant protein, the Anti-6×His antibody was set as the positive control (P) coated with His antigen, and the blank control was set at the same time (t...

Embodiment 2

[0228] Example 2 Using immunocytochemical staining to detect the expression of HPV16E7 protein in tumor cells fixed by liquid-based fixative

[0229] The CaSki and C-33A cells were collected by centrifugation in PBS, centrifuged to remove excess PBS, and then fixed with TCT fixative for 30 min. The fixed CaSki and C-33A cells were smeared on glass slides, soaked in 95% ethanol for 30 minutes, and air-dried overnight.

[0230] After the air-dried tumor cell coverslips were placed in 50% ethanol for 10 min, they were transferred to deionized water for at least 30 s. To prevent non-specific background staining, do not allow coverslips to dry out during staining. Place the deionized water-treated cell slides in Tris-EDTA (pH 9.0) repair solution, heat repair at 95-99°C for 10 minutes, rewarm at room temperature together with the repair solution for 20 minutes; spin dry, add PBST washing solution to wash 5min; shake dry, add 3% H to inactivate endogenous peroxidase 2 o 2 / PBS a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a monoclonal antibody capable of recognizing high-risk HPV E7 positive cervical epithelial cancer cells, and applications thereof. According to the present invention, the monoclonal antibody can highly specifically detect cervical cancer biomarkers HPV E7 protein in tumor cells, wherein the cervical cancer biomarker HPV E7 protein covers HPV16, HPV31, HPV35, HPV52 and HPV58 and other high-risk subtypes, such that cancerous cervical epithelial cells and abnormal cervix or non-cancerous cervical epithelial cells can be distinguishes so as to provide basis for the accurate diagnosis of HPV infection-induced cancers, effectively reduce the missed diagnosis of high-grade cervical lesions, provide complete time and complete basis for the diagnosis and the treatmentof patients by clinicians, improve the detection of early-stage cervical diseases and the early intervention, and reduce and avoid unnecessary colposcopy.

Description

technical field [0001] The invention belongs to the field of biological diagnosis and medicine. Specifically, the invention relates to a monoclonal antibody for identifying human papillomavirus (HPV) subtype 16 positive tumor cells, including human cervical epithelial cancer cells, and its application. Background technique [0002] Cervical cancer is the second most common female malignancy. About 500,000 women are diagnosed with cervical cancer every year in the world, and more than half of them die from it. The early symptoms of cervical cancer are not obvious, and there is a long and reversible precancerous lesion period in the development process. According to statistics, about 20% of low-grade cervical injuries will turn into high-grade injuries, and if not treated in time, 30% of them will further turn into malignant tumors. It takes about 10 years for the general cervical precancerous lesions to develop into cervical cancer. During this period, early diagnosis of pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/08C12N15/13A61K39/395A61P31/20A61P35/00G01N33/68G01N33/574G01N33/569
Inventor 常小迦刘岩时成龙韩凤丽施丽君
Owner ATTOGEN BIOMEDICAL SUZHOU INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap